Theratechnologies Inc. (NASDAQ: THTX) Stock Competitors & Peer Comparison
See THTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for THTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| THTX | $3.39 | +0.00% | 155.9M | -28.83 | -$0.12 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
THTX vs TAK Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TAK's P/E ratio is 12.52. In terms of profitability, THTX's ROE is +0.17%, compared to TAK's ROE of +0.02%. Regarding short-term risk, THTX is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for THTX.Check TAK's competition here
Haleon plc (NYSE: HLN)
THTX vs HLN Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas HLN's P/E ratio is 18.28. In terms of profitability, THTX's ROE is +0.17%, compared to HLN's ROE of +0.17%. Regarding short-term risk, THTX is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for THTX.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
THTX vs TEVA Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TEVA's P/E ratio is 12.54. In terms of profitability, THTX's ROE is +0.17%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, THTX is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
THTX vs VTRS Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas VTRS's P/E ratio is 6.39. In terms of profitability, THTX's ROE is +0.17%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, THTX is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for THTX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
THTX vs ITCI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ITCI's P/E ratio is -180.64. In terms of profitability, THTX's ROE is +0.17%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, THTX is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for THTX.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
THTX vs CTLT Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CTLT's P/E ratio is -27.84. In terms of profitability, THTX's ROE is +0.17%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, THTX is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for THTX.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
THTX vs ELAN Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ELAN's P/E ratio is 20.91. In terms of profitability, THTX's ROE is +0.17%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, THTX is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
THTX vs RDY Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas RDY's P/E ratio is 20.30. In terms of profitability, THTX's ROE is +0.17%, compared to RDY's ROE of +0.09%. Regarding short-term risk, THTX is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for THTX.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
THTX vs LNTH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas LNTH's P/E ratio is 16.93. In terms of profitability, THTX's ROE is +0.17%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, THTX is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for THTX.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
THTX vs AMRX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AMRX's P/E ratio is 19.62. In terms of profitability, THTX's ROE is +0.17%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, THTX is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
THTX vs INDV Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas INDV's P/E ratio is 10.61. In terms of profitability, THTX's ROE is +0.17%, compared to INDV's ROE of -2.16%. Regarding short-term risk, THTX is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for THTX.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
THTX vs SUPN Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SUPN's P/E ratio is 15.64. In terms of profitability, THTX's ROE is +0.17%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, THTX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
THTX vs RGC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas RGC's P/E ratio is -356.34. In terms of profitability, THTX's ROE is +0.17%, compared to RGC's ROE of -2.32%. Regarding short-term risk, THTX is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
THTX vs BHC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas BHC's P/E ratio is 1.58. In terms of profitability, THTX's ROE is +0.17%, compared to BHC's ROE of +0.89%. Regarding short-term risk, THTX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
THTX vs DCPH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas DCPH's P/E ratio is -11.58. In terms of profitability, THTX's ROE is +0.17%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, THTX is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for THTX.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
THTX vs HCM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas HCM's P/E ratio is 4.59. In terms of profitability, THTX's ROE is +0.17%, compared to HCM's ROE of +0.01%. Regarding short-term risk, THTX is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
THTX vs AVDL Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, THTX's ROE is +0.17%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, THTX is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for THTX.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
THTX vs EMBCV Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas EMBCV's P/E ratio is N/A. In terms of profitability, THTX's ROE is +0.17%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, THTX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for THTX.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
THTX vs DVAX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas DVAX's P/E ratio is -41.89. In terms of profitability, THTX's ROE is +0.17%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, THTX is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for THTX.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
THTX vs PRGO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PRGO's P/E ratio is 5.07. In terms of profitability, THTX's ROE is +0.17%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, THTX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
THTX vs ANIP Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ANIP's P/E ratio is 9.14. In terms of profitability, THTX's ROE is +0.17%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, THTX is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
THTX vs TARO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TARO's P/E ratio is 30.05. In terms of profitability, THTX's ROE is +0.17%, compared to TARO's ROE of +0.03%. Regarding short-term risk, THTX is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for THTX.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
THTX vs HROW Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas HROW's P/E ratio is 437.33. In terms of profitability, THTX's ROE is +0.17%, compared to HROW's ROE of -1.04%. Regarding short-term risk, THTX is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for THTX.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
THTX vs PAHC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PAHC's P/E ratio is 11.54. In terms of profitability, THTX's ROE is +0.17%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, THTX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
THTX vs ALVO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ALVO's P/E ratio is -11.79. In terms of profitability, THTX's ROE is +0.17%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, THTX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
THTX vs CRON Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CRON's P/E ratio is 30.10. In terms of profitability, THTX's ROE is +0.17%, compared to CRON's ROE of +0.06%. Regarding short-term risk, THTX is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for THTX.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
THTX vs ETON Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ETON's P/E ratio is -594.00. In terms of profitability, THTX's ROE is +0.17%, compared to ETON's ROE of -0.06%. Regarding short-term risk, THTX is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
THTX vs PCRX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PCRX's P/E ratio is 9.12. In terms of profitability, THTX's ROE is +0.17%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, THTX is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
THTX vs PETQ Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PETQ's P/E ratio is 83.73. In terms of profitability, THTX's ROE is +0.17%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, THTX is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for THTX.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
THTX vs AMPH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AMPH's P/E ratio is 6.82. In terms of profitability, THTX's ROE is +0.17%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, THTX is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for THTX.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
THTX vs COLL Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas COLL's P/E ratio is 3.26. In terms of profitability, THTX's ROE is +0.17%, compared to COLL's ROE of +0.16%. Regarding short-term risk, THTX is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for THTX.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
THTX vs EVO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, EVO has a market cap of 778M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas EVO's P/E ratio is -3.09. In terms of profitability, THTX's ROE is +0.17%, compared to EVO's ROE of -0.24%. Regarding short-term risk, THTX is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
THTX vs IRWD Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas IRWD's P/E ratio is 5.54. In terms of profitability, THTX's ROE is +0.17%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, THTX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for THTX.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
THTX vs BDSI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas BDSI's P/E ratio is 6.82. In terms of profitability, THTX's ROE is +0.17%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, THTX is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for THTX.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
THTX vs EOLS Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas EOLS's P/E ratio is -25.71. In terms of profitability, THTX's ROE is +0.17%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, THTX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for THTX.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
THTX vs AQST Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AQST's P/E ratio is -6.93. In terms of profitability, THTX's ROE is +0.17%, compared to AQST's ROE of +2.44%. Regarding short-term risk, THTX is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for THTX.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
THTX vs TLRY Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TLRY's P/E ratio is -4.32. In terms of profitability, THTX's ROE is +0.17%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, THTX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
THTX vs CGC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CGC's P/E ratio is -0.62. In terms of profitability, THTX's ROE is +0.17%, compared to CGC's ROE of -0.33%. Regarding short-term risk, THTX is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
THTX vs KMDA Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas KMDA's P/E ratio is 19.66. In terms of profitability, THTX's ROE is +0.17%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, THTX is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for THTX.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
THTX vs TKNO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TKNO's P/E ratio is -23.84. In terms of profitability, THTX's ROE is +0.17%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, THTX is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
THTX vs ALIM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ALIM's P/E ratio is 5.28. In terms of profitability, THTX's ROE is +0.17%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, THTX is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for THTX.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
THTX vs EMBC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas EMBC's P/E ratio is 1.83. In terms of profitability, THTX's ROE is +0.17%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, THTX is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
THTX vs LNDC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas LNDC's P/E ratio is -4.04. In terms of profitability, THTX's ROE is +0.17%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, THTX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
THTX vs ACB Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ACB's P/E ratio is -7.80. In terms of profitability, THTX's ROE is +0.17%, compared to ACB's ROE of -0.21%. Regarding short-term risk, THTX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
THTX vs ORGO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ORGO's P/E ratio is 60.33. In terms of profitability, THTX's ROE is +0.17%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, THTX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
THTX vs TYHT Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TYHT's P/E ratio is -1.61. In terms of profitability, THTX's ROE is +0.17%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, THTX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
THTX vs SIGA Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SIGA's P/E ratio is 10.63. In terms of profitability, THTX's ROE is +0.17%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, THTX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
THTX vs OGI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas OGI's P/E ratio is -4.96. In terms of profitability, THTX's ROE is +0.17%, compared to OGI's ROE of -0.07%. Regarding short-term risk, THTX is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for THTX.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
THTX vs LFCR Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas LFCR's P/E ratio is -4.46. In terms of profitability, THTX's ROE is +0.17%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, THTX is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for THTX.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
THTX vs REPH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas REPH's P/E ratio is -8.04. In terms of profitability, THTX's ROE is +0.17%, compared to REPH's ROE of -0.22%. Regarding short-term risk, THTX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for THTX.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
THTX vs DERM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas DERM's P/E ratio is -17.38. In terms of profitability, THTX's ROE is +0.17%, compared to DERM's ROE of -0.36%. Regarding short-term risk, THTX is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
THTX vs CRDL Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CRDL's P/E ratio is -5.41. In terms of profitability, THTX's ROE is +0.17%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, THTX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for THTX.Check CRDL's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
THTX vs ASRT Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ASRT's P/E ratio is -7.10. In terms of profitability, THTX's ROE is +0.17%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, THTX is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for THTX.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
THTX vs CPIX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CPIX's P/E ratio is -19.90. In terms of profitability, THTX's ROE is +0.17%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, THTX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
THTX vs SCTL Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SCTL's P/E ratio is -7.86. In terms of profitability, THTX's ROE is +0.17%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, THTX is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
THTX vs BGM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas BGM's P/E ratio is -1.01. In terms of profitability, THTX's ROE is +0.17%, compared to BGM's ROE of -0.07%. Regarding short-term risk, THTX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
THTX vs PROC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PROC's P/E ratio is 1.53. In terms of profitability, THTX's ROE is +0.17%, compared to PROC's ROE of -2.22%. Regarding short-term risk, THTX is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for THTX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
THTX vs OPTN Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas OPTN's P/E ratio is -4.42. In terms of profitability, THTX's ROE is +0.17%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, THTX is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for THTX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
THTX vs ZOM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ZOM's P/E ratio is -1.62. In terms of profitability, THTX's ROE is +0.17%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, THTX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
THTX vs GRVI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas GRVI's P/E ratio is 26.05. In terms of profitability, THTX's ROE is +0.17%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, THTX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for THTX.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
THTX vs ZYBT Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, THTX's ROE is +0.17%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, THTX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
THTX vs TLPH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TLPH's P/E ratio is -4.52. In terms of profitability, THTX's ROE is +0.17%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, THTX is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
THTX vs ZYNE Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, THTX's ROE is +0.17%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, THTX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
THTX vs SSIC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SSIC's P/E ratio is 11.93. In terms of profitability, THTX's ROE is +0.17%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, THTX is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
THTX vs VLNS Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas VLNS's P/E ratio is -1.03. In terms of profitability, THTX's ROE is +0.17%, compared to VLNS's ROE of N/A. Regarding short-term risk, THTX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for THTX.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
THTX vs DRRX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas DRRX's P/E ratio is -4.44. In terms of profitability, THTX's ROE is +0.17%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, THTX is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for THTX.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
THTX vs INCR Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas INCR's P/E ratio is -2.23. In terms of profitability, THTX's ROE is +0.17%, compared to INCR's ROE of -0.09%. Regarding short-term risk, THTX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for THTX.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
THTX vs JUPW Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas JUPW's P/E ratio is -2.41. In terms of profitability, THTX's ROE is +0.17%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, THTX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for THTX.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
THTX vs CPHI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CPHI's P/E ratio is -1.72. In terms of profitability, THTX's ROE is +0.17%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, THTX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for THTX.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
THTX vs QLI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas QLI's P/E ratio is -4.92. In terms of profitability, THTX's ROE is +0.17%, compared to QLI's ROE of -0.16%. Regarding short-term risk, THTX is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for THTX.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
THTX vs HEXO Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas HEXO's P/E ratio is -0.26. In terms of profitability, THTX's ROE is +0.17%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, THTX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for THTX.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
THTX vs RMTI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas RMTI's P/E ratio is -7.42. In terms of profitability, THTX's ROE is +0.17%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, THTX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for THTX.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
THTX vs AYTU Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AYTU's P/E ratio is -1.23. In terms of profitability, THTX's ROE is +0.17%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, THTX is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for THTX.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
THTX vs TXMD Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas TXMD's P/E ratio is 105.96. In terms of profitability, THTX's ROE is +0.17%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, THTX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for THTX.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
THTX vs CYTH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CYTH's P/E ratio is -0.80. In terms of profitability, THTX's ROE is +0.17%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, THTX is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for THTX.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
THTX vs EVOK Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas EVOK's P/E ratio is -7.97. In terms of profitability, THTX's ROE is +0.17%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, THTX is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for THTX.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
THTX vs OPTH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas OPTH's P/E ratio is -17.38. In terms of profitability, THTX's ROE is +0.17%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, THTX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for THTX.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
THTX vs ACRX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ACRX's P/E ratio is -0.31. In terms of profitability, THTX's ROE is +0.17%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, THTX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
THTX vs BFRIW Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, THTX's ROE is +0.17%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, THTX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for THTX.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
THTX vs COSM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas COSM's P/E ratio is -0.29. In terms of profitability, THTX's ROE is +0.17%, compared to COSM's ROE of -0.96%. Regarding short-term risk, THTX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
THTX vs AGRX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas AGRX's P/E ratio is -0.89. In terms of profitability, THTX's ROE is +0.17%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, THTX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
THTX vs NLTX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas NLTX's P/E ratio is -0.28. In terms of profitability, THTX's ROE is +0.17%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, THTX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for THTX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
THTX vs LCI Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas LCI's P/E ratio is -0.04. In terms of profitability, THTX's ROE is +0.17%, compared to LCI's ROE of +1.66%. Regarding short-term risk, THTX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for THTX.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
THTX vs ADMP Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ADMP's P/E ratio is -0.08. In terms of profitability, THTX's ROE is +0.17%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, THTX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for THTX.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
THTX vs YCBD Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas YCBD's P/E ratio is -1.49. In terms of profitability, THTX's ROE is +0.17%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, THTX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for THTX.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
THTX vs GELS Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas GELS's P/E ratio is -1.14. In terms of profitability, THTX's ROE is +0.17%, compared to GELS's ROE of -0.25%. Regarding short-term risk, THTX is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for THTX.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
THTX vs MNK Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas MNK's P/E ratio is -0.44. In terms of profitability, THTX's ROE is +0.17%, compared to MNK's ROE of -0.36%. Regarding short-term risk, THTX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for THTX.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
THTX vs FLGC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas FLGC's P/E ratio is -0.19. In terms of profitability, THTX's ROE is +0.17%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, THTX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
THTX vs UPC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas UPC's P/E ratio is -0.75. In terms of profitability, THTX's ROE is +0.17%, compared to UPC's ROE of -0.03%. Regarding short-term risk, THTX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
THTX vs SBFM Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SBFM's P/E ratio is -0.20. In terms of profitability, THTX's ROE is +0.17%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, THTX is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
THTX vs PLXP Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PLXP's P/E ratio is -0.22. In terms of profitability, THTX's ROE is +0.17%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, THTX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for THTX.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
THTX vs SHPH Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SHPH's P/E ratio is -0.20. In terms of profitability, THTX's ROE is +0.17%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, THTX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
THTX vs ATNX Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas ATNX's P/E ratio is -0.02. In terms of profitability, THTX's ROE is +0.17%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, THTX is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for THTX.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
THTX vs SNOA Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SNOA's P/E ratio is -1.16. In terms of profitability, THTX's ROE is +0.17%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, THTX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
THTX vs PROCW Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas PROCW's P/E ratio is N/A. In terms of profitability, THTX's ROE is +0.17%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, THTX is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for THTX.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
THTX vs RDHL Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas RDHL's P/E ratio is 0.12. In terms of profitability, THTX's ROE is +0.17%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, THTX is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for THTX.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
THTX vs SXTC Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas SXTC's P/E ratio is 1.18. In terms of profitability, THTX's ROE is +0.17%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, THTX is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for THTX.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
THTX vs YCBD-PA Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, THTX's ROE is +0.17%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, THTX is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for THTX.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
THTX vs CYTHW Comparison August 2026
Theratechnologies Inc. (NASDAQ: THTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, THTX stands at 155.9M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, THTX is priced at $3.39 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
THTX currently has a P/E ratio of -28.83, whereas CYTHW's P/E ratio is N/A. In terms of profitability, THTX's ROE is +0.17%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, THTX is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for THTX.Check CYTHW's competition here